It was clearly demonstrated that PSMA PET/CT cannot replace histopathological lymph node evaluation using ePLND specimens, due to the lymph node tumor burden-dependency of PSMA avidity [14,15,16]. This evidence concerns the gene FOLH1 and neoplasm.